Browsing Tag
cancer
122 posts
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize…
Debiopharm, ThinkingNodeLife.ai join forces to advance AI-driven cancer drug development
Debiopharm, an independent biopharmaceutical company based in Switzerland, has forged a collaborative partnership with USA’s ThinkingNodeLife.ai (TNL), a…
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the…
FDA approves Ryzneuta by Evive Biotech for reducing febrile neutropenia in cancer patients
Evive Biotech, a global biopharmaceutical company and a subsidiary of Yifan Pharmaceutical Co. Ltd., along with New Jersey-based…
ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio…
Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of…
Venus Remedies expands cancer drug portfolio in South Eastern Europe
In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted…
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a…
ENB Therapeutics completes Phase 1 trial enrollment for ENB-003
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of…
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab…